Phase 2Terminated
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Sponsor
- Processa Pharmaceuticals (Industry)
- Enrollment
- 20 enrolled
- Conditions
- Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer
- Interventions
- PCS6422 and capecitabine; Capecitabine
- Ages
- adults, older adults
- Registry
- NCT06568692
Full record on ClinicalTrials.gov
From the registry
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.
Primary outcomes
- Evaluation of Objective Response Rate (ORR)
- Number of patients with adverse events (AEs)
History
Last registry update
Primary completion
Started
Registered